Shibeikang Showcases Core Pipeline and AI-Powered Drug Discovery Platform at BCVS 2026 and Asian Cardiovascular Symposium (ACS)

In July 2026, Chengdu Shibeikang Biomedical Technology Co., Ltd. participated in the Basic Cardiovascular Sciences (BCVS) Scientific Sessions organized by the American Heart Association (AHA), as well as the 8th Annual Asian Cardiovascular Symposium (ACS), co-organized by the Academy of Cardiovascular Research Excellence (ACRE). The company engaged in academic exchanges with leading cardiovascular experts, clinicians, and industry representatives from around the world, and delivered a keynote address at the ACS Symposium to share the progress of its core pipeline and AI-powered drug discovery platform.

Advancing Global Collaboration Through Leading Cardiovascular Platforms

BCVS 2026 Scientific Sessions: Organized by the American Heart Association (AHA) under the leadership of AHA President Professor Manesh R. Patel, the event serves as a leading global forum for basic and translational cardiovascular science. It brings together experts from research, clinical practice, and industry to advance innovation in cardiovascular research, translational medicine, and clinical applications.
8th Annual Asian Cardiovascular Symposium: Co-organized by the Academy of Cardiovascular Research Excellence (ACRE), the symposium focuses on the latest advances in cardiovascular research and promotes collaboration among academia, research institutions, and industry. The event provides a professional platform connecting North America and Asia while facilitating global exchange and innovation in cardiovascular science.

Sharing Pipeline Progress and Highlighting AI-Enabled R&D Capabilities

At the ACS Symposium, the Head of the Medical Marketing at Shibeikang delivered a keynote address titled Shibeikang's Current R&D Pipeline: Key Candidates and Development Status, providing a systematic overview of the company’s R&D landscape and the progress of its core pipeline.

The presentation highlighted recent development updates for SBK001, a next-generation expectorant; sbk002 (Becondogrel), an antiplatelet agent; and SBK007, a third-generation antihistamine. It also showcased the potential value of these programs in addressing unmet clinical needs, supported by their differentiated safety and efficacy profiles.

Shibeikang also shared practical achievements from its AI-powered metabolically differentiated R&D platform. Leveraging this intelligent R&D system, the company has developed a standardized, end-to-end innovation workflow covering target discovery, preclinical research, process optimization, and clinical translation. This platform provides integrated technical support to enable more precise and efficient development of innovative therapies.

The presentation attracted significant attention and received positive feedback from participating experts.